PCA Neurotoxin Administration
Objective: To examine whether chronic parenchymal administration of neurotrophins (BDNF, NT-3, or NGF) can prevent the severe degenerative loss of serotonergic axons caused by the selective 5-HT neurotoxin p-chloroamphetamine (PCA)
This is a PCA Neurotoxin Administration protocol using rat as the model organism. The procedure involves 5 procedural steps, 2 equipment items, 6 materials. Extracted from a 1995 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
~3 week study window
Core workflow
Osmotic minipump implantation and neurotrophin infusion initiation • PCA or vehicle administration • Continued neurotrophin infusion
Primary readouts
- 5-HT axon density in 3 mm diameter region surrounding cannula tip (measured by 5-HT immunocytochemistry)
- 5-HT content near infusion cannula (neurochemical analysis)
- 5-HIAA content near infusion cannula (neurochemical analysis)
- 3H-5-HT uptake near infusion cannula (neurochemical analysis)
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Osmotic minipump implantation and neurotrophin infusion initiation
Osmotic minipumps delivering neurotrophins (BDNF, NT-3, or NGF at 5-12 micrograms/d) or control substances (cytochrome c or PBS vehicle) were implanted to continuously infuse into the rat frontoparietal cortex
Note: Infusion cannula placement in frontoparietal cortex; baseline timepoint for subsequent PCA administration
View evidence from paper
“The neurotrophins (5–12 micrograms/d) or the control substances (cytochrome c or PBS vehicle) were continuously infused into the rat frontoparietal cortex using an osmotic minipump”
PCA or vehicle administration
One week after osmotic minipump implantation, rats were subcutaneously administered either PCA (10 mg/kg) or vehicle control
Note: Timing allows for establishment of neurotrophin infusion before neurotoxic challenge
View evidence from paper
“One week later, rats were subcutaneously administered PCA (10 mg/kg) or vehicle”
Continued neurotrophin infusion
Neurotrophin infusion continued for two additional weeks following PCA or vehicle administration
Note: Total infusion period is 3 weeks; 2 weeks of infusion occur after PCA administration
View evidence from paper
“the 5-HT innervation was evaluated after two more weeks of neurotrophin infusion”
5-HT immunocytochemistry evaluation
Serotonergic axon density was evaluated using 5-HT immunocytochemistry in a 3 mm diameter region surrounding the cannula tip
Note: Primary outcome measure for assessing neurotrophin effects on 5-HT axon density and PCA-induced degeneration
View evidence from paper
“As revealed with 5-HT immunocytochemistry, BDNF infusions into the neocortex of intact (non-PCA-lesioned) rats caused a substantial increase in 5-HT axon density in a 3 mm diameter region surrounding the cannula tip”
Neurochemical evaluation
Neurochemical assessments were performed to measure 5-HT and 5-HIAA contents and 3H-5-HT uptake near the infusion cannula
Note: Supportive biochemical measures to confirm immunocytochemical findings
View evidence from paper
“The immunocytochemical data were supported by neurochemical evaluations which showed that BDNF attenuated the PCA-induced loss of 5-HT and 5-HIAA contents and 3H-5-HT uptake near the infusion cannula”